Company Overview
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company focused on developing treatments for serious diseases utilizing novel soluble guanylate cyclase (sGC) stimulators within both the central nervous system and the periphery. The firm specifically highlights the development of Olinciguat, an orally administered vascular sGC stimulator, as a core component of its therapeutic pipeline. This biotechnology entity functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address significant medical needs through innovative drug discovery and development processes. As of the latest data, the company maintains a market capitalization of $5.73M and reports annual revenue of $2.85M, supported by an operational team consisting of 1 employee. The combination of a market cap under $10 million and revenue below $3 million indicates that Cyclerion is a micro-cap entity with limited scale, suggesting that its valuation is driven primarily by the potential future value of its drug candidates rather than established commercial earnings.
Financial Health
The company reported revenue of $2.85M over the trailing twelve months, while recording a net income of $-2,199,000 and an EBITDA metric that is not applicable due to lack of profitability. The substantial negative gap between the $2.85M revenue and the $-2.199M net income reveals a cost structure characterized by heavy research and development expenditures that exceed current revenue generation, which is typical for early-stage biotechnology firms. Free cash flow stands at $-1,446,625, indicating that the company is currently burning cash to fund its operations and pipeline advancement rather than generating surplus liquidity for immediate distribution or debt repayment. Gross margin is reported at 92.6%, reflecting high revenue retention on individual sales, while the operating margin sits at -115.0% and the profit margin is -77.0%, illustrating that the company is operating at a significant loss on every dollar of revenue generated. Total cash reserves amount to $4.57M, whereas total debt is not applicable, resulting in a debt-to-equity ratio that is not applicable and a balance sheet that appears conservative regarding leverage. The current ratio is 5.78, which indicates a robust ability to meet short-term obligations with current assets significantly exceeding current liabilities despite the lack of traditional debt. Return on equity is -24.8% and return on assets is -23.5%, metrics that reveal that management effectiveness in generating profit from shareholder equity and total assets is currently negative due to the company's developmental stage and lack of earnings.
Valuation Assessment
The trailing P/E ratio is not applicable, while the forward P/E is -1.15, implying that the market is currently pricing the stock based on non-earnings fundamentals as the company has not yet achieved positive earnings. The price-to-book ratio stands at 0.58, which indicates that the market is valuing the company at approximately 42% below its book value, suggesting a discount often seen in speculative biotechnology stocks with unproven commercial products. The price-to-sales ratio is 2.01, and since EV/EBITDA is not applicable, these alternative valuation metrics suggest that investors are relying heavily on revenue multiples to assess the company's worth in the absence of traditional earnings-based valuation methods. The 52-week high is $3.79 and the 52-week low is $1.03, establishing a trading range where the current price position relative to these extremes defines the stock's recent volatility and investor sentiment. The beta value is 1.02, which means the stock exhibits a price volatility that is slightly more sensitive to market movements than the broader market, tracking very closely with general market fluctuations.
Growth & Income
Revenue growth year-over-year is 351.0%, while earnings growth year-over-year is not applicable, indicating that while the top line is expanding rapidly, the company has not yet reached a stage where earnings are growing in tandem with revenue. Because the company is not a dividend payer, there is no dividend yield or payout ratio to analyze for sustainability; instead, the company reinvests its limited earnings and cash reserves directly into research and development to advance its drug candidates. The overall growth profile is defined by aggressive top-line expansion in the $2.85M revenue range, whereas the income profile remains negative with a net loss of $2.199M, reflecting the capital-intensive nature of the biotechnology industry during the pre-revenue or early-revenue phases.